Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HT008 is a standardized botanical extract developed by Neumed for the improvement of joint health and the management of osteoarthritis symptoms. It is a complex mixture derived from three medicinal herbs: *Eleutherococcus senticosus* (Siberian ginseng), *Achyranthes bidentata*, and *Phlomis umbrosa*. The extract exerts its therapeutic effects through multiple anti-inflammatory and chondroprotective pathways. Specifically, it inhibits the production of pro-inflammatory mediators such as prostaglandin E2 (PGE2) and cytokines including interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α). Furthermore, HT008 helps preserve joint integrity by suppressing the expression of matrix metalloproteinases (MMPs), such as MMP-1, MMP-3, and MMP-13, which are responsible for the degradation of the articular cartilage extracellular matrix. In South Korea, HT008 has been recognized by the Ministry of Food and Drug Safety (MFDS) as a functional ingredient for joint health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HT008.